Drilldown: Medicines
Medicines > classes 
:
Anticonvulsant or
Benzodiazepine or
[[:Category:Dopamine agonists|Dopamine D2/D3 receptor agonist (non-ergot)]]
:
Anticonvulsant or
Benzodiazepine or
[[:Category:Dopamine agonists|Dopamine D2/D3 receptor agonist (non-ergot)]] Use the filters below to narrow your results.
generic:
brand:
None (9) ·
Aptiom (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Dalmane (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Doral (1) ·
Epidiolex (1) ·
Felbatol (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
Halcion (1) ·
Lexotan (1) ·
Librium (1) ·
Luminal (1) ·
Mirapex (IR), Mirapex ER (1) ·
Mogadon (1) ·
Onfi (1) ·
ProSom (1) ·
Requip (IR), Requip XL (extended-release) (1) ·
Restoril (1) ·
Rohypnol (1) ·
Sabril (1) ·
Serax (1) ·
Tranxene (1) ·
Versed (1) ·
Vimpat (1) ·
Xanax (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
AMPA receptor antagonist (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1)
uses:
None (40) ·
'"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (1) ·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
starting dose:
None (40) ·
0.25 mg (1) ·
Parkinson disease: 0.125 mg PO TID, titrate weekly to maintenance ~1.5 mg TID. Restless legs syndrome: 0.125 mg PO 2-3 hours before bedtime, titrate to 0.5 mg/day if needed (1) ·
Parkinson disease: 0.25 mg PO TID, titrate weekly. Restless legs syndrome: 0.25 mg PO 1-3 hours before bedtime, titrate to 4 mg/day if needed (1)
preparations:
None (40) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
IR tablets 0.125, 0.25, 0.5, 0.75, 1, 1.5 mg; ER tablets 0.375, 0.75, 1.5, 2.25, 3, 3.75, 4.5 mg (1) ·
IR tablets 0.25, 0.5, 1, 2, 3, 4, 5 mg; XL tablets 2, 4, 6, 8, 12 mg (1)
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (40) ·
Category D'"`UNIQ--ref-0000006C-QINU`"' (1) ·
Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; rarely indicated in pregnancy given the typical patient population.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 44 results in range #1 to #44.
A
B
C
D
E
F
- Fenfluramine
- Flualprazolam
- Flubromazepam
- Flubromazolam
- Flunitrazepam
- Flunitrazolam
- Flurazepam
- Fosphenytoin